Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study to Evaluate Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants (V350-001).

Merck Sharp & Dohme LLC · NCT06655324

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 12–30 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
250
US sites recruiting
6
Study start
December 5, 2024
Record last updated
September 17, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Epstein Barr virus (EBV) is a virus which can cause infectious mononucleosis and is associated with certain kinds of cancer and multiple sclerosis. Researchers are looking for new ways to prevent disease related to EBV and have developed a new study vaccine (V350A and V350B). The main goal of this study is to learn about the safety and tolerability of V350A and V350B in healthy adults.

Being studied: V350A; V350B; Placebo

Conditions: Healthy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization.
  • Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17.

Exclusion Criteria

The key exclusion criteria include but are not limited to the following:

  • Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment.
  • Has any immunosuppressive medical condition or receive any immunosuppressive therapy.

Recruiting US locations

  • Alliance for Multispecialty Research, LLC ( Site 0008)

    Kansas City, MO 64114

    Site contact: Study Coordinator · 816-943-0770

  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)

    Springfield, MO 65802

    Site contact: Study Coordinator · 417-831-2048

  • Velocity Clinical Research Lincoln ( Site 0004)

    Lincoln, NE 68510

    Site contact: Study Coordinator · 308-365-8900

  • Velocity Clinical Research, Omaha ( Site 0005)

    Omaha, NE 68134

    Site contact: Study Coordinator · 402-933-6500

  • Remington-Davis, Inc. ( Site 0017)

    Columbus, OH 43215

    Site contact: Study Coordinator · 614-487-2560

  • Lynn Health Science Institute ( Site 0010)

    Oklahoma City, OK 73112

    Site contact: Study Coordinator · 405-602-3939

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All healthy volunteers studies in Missouri →
A Study to Evaluate Safety, Tolerability, and Immunogenicity of… (NCT06655324) | Bored Studies